These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37771591)

  • 1. Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK.
    Li L; Zhao M; Kiernan CH; Castro Eiro MD; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Mueller YM; Katsikis PD
    Front Immunol; 2023; 14():1201415. PubMed ID: 37771591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation.
    Zhao M; Kiernan CH; Stairiker CJ; Hope JL; Leon LG; van Meurs M; Brouwers-Haspels I; Boers R; Boers J; Gribnau J; van IJcken WFJ; Bindels EM; Hoogenboezem RM; Erkeland SJ; Mueller YM; Katsikis PD
    PLoS Pathog; 2020 Jun; 16(6):e1008555. PubMed ID: 32579593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer.
    Deng G; He J; Huang Q; Li T; Huang Z; Gao S; Xu J; Wang T; Di J
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition.
    Zhao M; Li L; Kiernan CH; Castro Eiro MD; Dammeijer F; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Aerts JG; Mueller YM; Katsikis PD
    Sci Rep; 2023 Sep; 13(1):15678. PubMed ID: 37735204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model.
    Lutz V; Hellmund VM; Picard FSR; Raifer H; Ruckenbrod T; Klein M; Bopp T; Savai R; Duewell P; Keber CU; Weigert A; Chung HR; Buchholz M; Menke A; Gress TM; Huber M; Bauer C
    Cancer Immunol Res; 2023 Apr; 11(4):421-434. PubMed ID: 36758176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
    Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model.
    Hope JL; Spantidea PI; Kiernan CH; Stairiker CJ; Rijsbergen LC; van Meurs M; Brouwers-Haspels I; Mueller YM; Nelson DJ; Bradley LM; Aerts JGJV; Katsikis PD
    Front Immunol; 2019; 10():3074. PubMed ID: 31998326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.
    Wang JD; Chen XY; Ji KW; Tao F
    Am J Transl Res; 2016; 8(7):3003-12. PubMed ID: 27508020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcription factor Eomes promotes expression of inhibitory receptors on hepatic CD8
    Yu L; Guan Y; Li L; Lu N; Zhang C
    FEBS J; 2022 Jun; 289(11):3241-3261. PubMed ID: 34986510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.
    Xu A; Wang R; Freywald A; Stewart K; Tikoo S; Xu J; Zheng C; Xiang J
    Biochem Biophys Res Commun; 2017 Mar; 484(3):662-667. PubMed ID: 28153727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.